Cargando…

COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies

Coronavirus-triggered pulmonary and systemic disease, i.e. systemic inflammatory response to virally triggered lung injury, named COVID-19, and ongoing discussions on refining immunomodulation in COVID-19 without COX2 inhibition prompted us to search the related literature to show a potential target...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baghaki, Semih, Yalcin, Can Ege, Baghaki, Hayriye Sema, Aydin, Servet Yekta, Daghan, Basak, Yavuz, Ersin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7525269/ https://www.ncbi.nlm.nih.gov/pubmed/33007455 http://dx.doi.org/10.1016/j.ijid.2020.09.1466

Ejemplares similares

Joint frequency offset, time offset, and channel estimation for OFDM/OQAM systems
por: Baghaki, Ali, et al.
Publicado: (2018)

Risk Assessment of Surgical Interventions Performed on Non-Infected Patients During COVID-19 Pandemic
por: Demiroz, Anıl, et al.
Publicado: (2020)

Multifocal Fixed Drug Eruption with COX-2 Inhibitor-Celecoxib
por: Chugh, Shikha, et al.
Publicado: (2013)

Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
por: Howes, Laurence Guy
Publicado: (2007)

Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
por: Walker, Chris
Publicado: (2018)

Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”
por: Walker, Chris
Publicado: (2019)

COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro
por: Chuang, Huan-Ching, et al.
Publicado: (2008)

Investigation of the effects of clinical parameters on mortality in patients with necrotizing fasciitis
por: Yekta Aydın, Servet, et al.
Publicado: (2023)

Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives
por: Reimann, Hauke, et al.
Publicado: (2020)

The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: An intravital microscopy study in mice
por: Klenke, Frank Michael, et al.
Publicado: (2006)

Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms
por: Liu, B, et al.
Publicado: (2011)

Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms
por: Liu, B, et al.
Publicado: (2011)

Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells
por: Gharghabi, Mehdi, et al.
Publicado: (2016)

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer
por: Tury, Sandrine, et al.
Publicado: (2016)

Celecoxib, a selective COX-2 inhibitor, markedly reduced the severity of tamoxifen-induced adenomyosis in a murine model
por: Jin, Zhixing, et al.
Publicado: (2020)

COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function
por: Veltman, Joris D, et al.
Publicado: (2010)

Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling
por: Al-Rashed, Fahad, et al.
Publicado: (2018)

Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus)
por: Dhondt, Laura, et al.
Publicado: (2017)

Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit
por: Oliva, Claudia R., et al.
Publicado: (2017)

COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia
por: Farooqui, M, et al.
Publicado: (2007)

In Vivo Brain Imaging, Biodistribution, and Radiation Dosimetry Estimation of [(11)C]Celecoxib, a COX-2 PET Ligand, in Nonhuman Primates
por: Kumar, J. S. Dileep, et al.
Publicado: (2018)

Low-dose cyclooxygenase-2 (COX-2) inhibitor celecoxib plays a protective role in the rat model of neonatal necrotizing enterocolitis
por: Sun, Ling
Publicado: (2021)

Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX‐2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis
por: Shirata, Toshinori, et al.
Publicado: (2023)

Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and Tolcapone as Potential Therapeutics for Colorectal Cancers
por: Beklen, Hande, et al.
Publicado: (2021)

Celecoxib Alleviates Memory Deficits by Downregulation of COX-2 Expression and Upregulation of the BDNF-TrkB Signaling Pathway in a Diabetic Rat Model
por: Yang, Ying, et al.
Publicado: (2017)

Celecoxib Analogues for Cancer Treatment: An Update on OSU-03012 and 2,5-Dimethyl-Celecoxib
por: Sobolewski, Cyril, et al.
Publicado: (2021)

Vismodegib Identified as a Novel COX-2 Inhibitor via Deep-Learning-Based Drug Repositioning and Molecular Docking Analysis
por: Yasir, Muhammad, et al.
Publicado: (2023)

Celecoxib effectively inhibits the formation of joint adhesions
por: LI, FENGFENG, et al.
Publicado: (2013)

Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations
por: Scolnik, Marina, et al.
Publicado: (2011)

Challenges and Opportunities for Celecoxib Repurposing
por: Bąk, Urszula, et al.
Publicado: (2023)

Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib
por: Lee, Yonghyun, et al.
Publicado: (2020)

Systems-level biomarkers identification and drug repositioning in colorectal cancer
por: Beklen, Hande, et al.
Publicado: (2021)

Repositioning of Anti-Inflammatory Drugs for the Treatment of Cervical Cancer Sub-Types
por: Kori, Medi, et al.
Publicado: (2022)

Cellular and molecular studies of the effects of a selective COX-2 inhibitor celecoxib in the cardiac cell line H9c2 and their correlation with death mechanisms
por: Sakane, K.K., et al.
Publicado: (2013)

Lip repositioning
por: Gaddale, Reetika, et al.
Publicado: (2014)

Triggering of Suicidal Erythrocyte Death by Celecoxib
por: Lupescu, Adrian, et al.
Publicado: (2013)

Reappraisal of the Therapeutic Role of Celecoxib in Cholangiocarcinoma
por: Yeh, Chun-Nan, et al.
Publicado: (2013)

Celecoxib in breast cancer prevention and therapy
por: Li, Jieqing, et al.
Publicado: (2018)

The molecular mechanisms of celecoxib in tumor development
por: Wen, Bin, et al.
Publicado: (2020)

Combination of fasudil and celecoxib promotes the recovery of injured spinal cord in rats better than celecoxib or fasudil alone
por: Hou, Xiao-lin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lejm4abpkccd930ijv21629d1v